Ministry of Science & Technology press release · 9 March 2026 · pibtracker filter

TDB-DST SUPPORTS BABYCUE PVT. LTD., CUTTACK (ODISHA) FOR DEVELOPMENT OF RAPID DIAGNOSTIC PLATFORM FOR CHILDHOOD DIARRHEA

PRID2236903 MinistryMinistry of Science & Technology Released9 March 2026 Reading10 min

Posted On: 09 MAR 2026 2:32PM by PIB Delhi The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial support to M/s BabyCue Private Limited, Cuttack (Odisha) for its project titled “A Disposable Paper Analytical Platform for Rapid Differentiation of Childhood Diarrhea.” The project focuses on the commercialization of an indigenous rapid diagnostic kit designed to enable timely and accurate differentiation between bacterial and non-bacterial diarrhea in children. The proposed product, DiaCue Diagnostic Kit, represents a significant indigenous innovation integrating biotechnology and material science to address the widespread public health challenge of childhood diarrhea in India. The kit is designed as a rapid, non-invasive, and cost-effective point-of-care diagnostic solution that can be deployed even in resource-constrained environments such as rural health centers and field settings. The DiaCue platform is based on Lateral Flow Assay (LFA) technology that utilizes disease-specific fecal biomarkers for rapid detection. The system employs gold nanoparticle–based colorimetric detection, allowing results to be interpreted visually without the need for specialized laboratory instruments. The use of proprietary biomarkers and custom-designed reagents ensures high sensitivity and specificity, enabling reliable differentiation between bacterial and non-bacterial infections. The testing process is simple and suitable for point-of-care applications. A fresh stool sample is collected using a sample loop or swab and mixed with an extraction buffer. After settling, the clear supernatant is applied onto the LFA strip, where it migrates and interacts with immobilized reagents to produce a visible color change. The presence or absence of colored lines on the strip indicates whether the infection is bacterial or non-bacterial, enabling rapid clinical decision-making within minutes. Key advantages of the DiaCue diagnostic platform include rapid differentiation of bacterial and non-bacterial diarrhea, reduction in unnecessary antibiotic usage and antimicrobial resistance, ease of use in both clinical and field environments, and minimal dependence on sophisticated laboratory infrastructure. The technology has been developed in collaboration with National Institute of Pharmaceutical Education and Research Hyderabad and clinically validated at ESIC Hospital Hyderabad. The proprietary biomarker detection methodology is protected under an international patent filing, ensuring intellectual property protection and enabling scalable commercialization. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, “Indigenous innovations in rapid diagnostics are essential for strengthening primary healthcare delivery and improving clinical decision-making. By supporting the commercialization of the DiaCue diagnostic platform, TDB aims to promote affordable, accessible, and technology-driven healthcare solutions that address critical public health challenges such as childhood diarrhea.” Promoters of BabyCue Private Limited expressed gratitude for the support and noted that the assistance from TDB will enable the company to accelerate product development, scale manufacturing capabilities, and deploy the diagnostic solution widely to benefit healthcare providers and patients. ***** NKR/FK/NM (Release ID: 2236903) Visitor Counter : 744 Read this release in: Urdu , हिन्दी , Odia Ministry of Science & Technology TDB-DST SUPPORTS BABYCUE PVT. LTD., CUTTACK (ODISHA) FOR DEVELOPMENT OF RAPID DIAGNOSTIC PLATFORM FOR CHILDHOOD DIARRHEA Posted On: 09 MAR 2026 2:32PM by PIB Delhi The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial support to M/s BabyCue Private Limited, Cuttack (Odisha) for its project titled “A Disposable Paper Analytical Platform for Rapid Differentiation of Childhood Diarrhea.” The project focuses on the commercialization of an indigenous rapid diagnostic kit designed to enable timely and accurate differentiation between bacterial and non-bacterial diarrhea in children. The proposed product, DiaCue Diagnostic Kit, represents a significant indigenous innovation integrating biotechnology and material science to address the widespread public health challenge of childhood diarrhea in India. The kit is designed as a rapid, non-invasive, and cost-effective point-of-care diagnostic solution that can be deployed even in resource-constrained environments such as rural health centers and field settings. The DiaCue platform is based on Lateral Flow Assay (LFA) technology that utilizes disease-specific fecal biomarkers for rapid detection. The system employs gold nanoparticle–based colorimetric detection, allowing results to be interpreted visually without the need for specialized laboratory instruments. The use of proprietary biomarkers and custom-designed reagents ensures high sensitivity and specificity, enabling reliable differentiation between bacterial and non-bacterial infections. The testing process is simple and suitable for point-of-care applications. A fresh stool sample is collected using a sample loop or swab and mixed with an extraction buffer. After settling, the clear supernatant is applied onto the LFA strip, where it migrates and interacts with immobilized reagents to produce a visible color change. The presence or absence of colored lines on the strip indicates whether the infection is bacterial or non-bacterial, enabling rapid clinical decision-making within minutes. Key advantages of the DiaCue diagnostic platform include rapid differentiation of bacterial and non-bacterial diarrhea, reduction in unnecessary antibiotic usage and antimicrobial resistance, ease of use in both clinical and field environments, and minimal dependence on sophisticated laboratory infrastructure. The technology has been developed in collaboration with National Institute of Pharmaceutical Education and Research Hyderabad and clinically validated at ESIC Hospital Hyderabad. The proprietary biomarker detection methodology is protected under an international patent filing, ensuring intellectual property protection and enabling scalable commercialization. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, “Indigenous innovations in rapid diagnostics are essential for strengthening primary healthcare delivery and improving clinical decision-making. By supporting the commercialization of the DiaCue diagnostic platform, TDB aims to promote affordable, accessible, and technology-driven healthcare solutions that address critical public health challenges such as childhood diarrhea.” Promoters of BabyCue Private Limited expressed gratitude for the support and noted that the assistance from TDB will enable the company to accelerate product development, scale manufacturing capabilities, and deploy the diagnostic solution widely to benefit healthcare providers and patients. ***** NKR/FK/NM (Release ID: 2236903) The Technology Development Board (TDB), Department of Science & Technology (DST), Government of India, has extended financial support to M/s BabyCue Private Limited, Cuttack (Odisha) for its project titled “A Disposable Paper Analytical Platform for Rapid Differentiation of Childhood Diarrhea.” The project focuses on the commercialization of an indigenous rapid diagnostic kit designed to enable timely and accurate differentiation between bacterial and non-bacterial diarrhea in children. The proposed product, DiaCue Diagnostic Kit, represents a significant indigenous innovation integrating biotechnology and material science to address the widespread public health challenge of childhood diarrhea in India. The kit is designed as a rapid, non-invasive, and cost-effective point-of-care diagnostic solution that can be deployed even in resource-constrained environments such as rural health centers and field settings. The DiaCue platform is based on Lateral Flow Assay (LFA) technology that utilizes disease-specific fecal biomarkers for rapid detection. The system employs gold nanoparticle–based colorimetric detection, allowing results to be interpreted visually without the need for specialized laboratory instruments. The use of proprietary biomarkers and custom-designed reagents ensures high sensitivity and specificity, enabling reliable differentiation between bacterial and non-bacterial infections. The testing process is simple and suitable for point-of-care applications. A fresh stool sample is collected using a sample loop or swab and mixed with an extraction buffer. After settling, the clear supernatant is applied onto the LFA strip, where it migrates and interacts with immobilized reagents to produce a visible color change. The presence or absence of colored lines on the strip indicates whether the infection is bacterial or non-bacterial, enabling rapid clinical decision-making within minutes. Key advantages of the DiaCue diagnostic platform include rapid differentiation of bacterial and non-bacterial diarrhea, reduction in unnecessary antibiotic usage and antimicrobial resistance, ease of use in both clinical and field environments, and minimal dependence on sophisticated laboratory infrastructure. The technology has been developed in collaboration with National Institute of Pharmaceutical Education and Research Hyderabad and clinically validated at ESIC Hospital Hyderabad. The proprietary biomarker detection methodology is protected under an international patent filing, ensuring intellectual property protection and enabling scalable commercialization. Speaking on the occasion, Shri Rajesh Kumar Pathak, Secretary, TDB, stated, “Indigenous innovations in rapid diagnostics are essential for strengthening primary healthcare delivery and improving clinical decision-making. By supporting the commercialization of the DiaCue diagnostic platform, TDB aims to promote affordable, accessible, and technology-driven healthcare solutions that address critical public health challenges such as childhood diarrhea.” Promoters of BabyCue Private Limited expressed gratitude for the support and noted that the assistance from TDB will enable the company to accelerate product development, scale manufacturing capabilities, and deploy the diagnostic solution widely to benefit healthcare providers and patients. <img src="https://static.pib.gov.in/WriteReadData/userfiles/image/image001AXZC.jpg" style="height:233px; width:602px" /> ***** NKR/FK/NM  " /> var mPlayer = document.getElementById("background_music"); var mPlayAction = document.getElementById("playbutton"); var isPlaying = false; function playAudio() { mPlayer.play(); isPlaying = true; document.getElementById('stopA').style.display = "block"; document.getElementById('playA').style.display = "none"; } function pauseAudio() { mPlayer.pause(); isPlaying = false; document.getElementById('playA').style.display = "block"; document.getElementById('stopA').style.display = "none"; } //function HandleAudio() { // if (isPlaying == true) { // //Playing already Pause it // pauseAudio(); // } else { // //Play the music // playAudio(); // } //} var synth = window.speechSynthesis; function CleanHtml(html) { html = html.replace(/ /gi, ''); return html; } function stripHtml(html) { let tmp = document.createElement("DIV"); tmp.innerHTML = CleanHtml(html); return tmp.textContent || tmp.innerText || ""; } $(document).ready(function () { //for responsive tables $("table").each(function () { if (!$(this).closest(".table-responsive").length) { $(this).wrap(" "); } }); var width = $(window).width(); if (width $(document).ready(function () { var width = $(window).width(); if (width @media print { .sticky-social, .sticky-social_mb, .pull-right, #printPDF { display: none !important; } } .f_vl { padding-right: 30px; font-size: 17px; cursor: pointer; } .log_oo { // width: 20%; display: flex; justify-content: space-between; } .log_oo img { width: 150px; /*width: 100%; height: auto;*/ } .sticky-social_mb { position: fixed; bottom: 0px; padding: 0px; margin: 0px; width: 100%; } .social_mb { list-style: none; display: flex; width: 100%; margin-bottom: -8px; } .social_mb a { padding: 8px 0px; font-size: 30px; transition: all 0.8s ease-in-out; width: 20% !important; text-align: center; } .section1 { position: relative; padding: 10px 0px; width: 100%; } .sticky-social { position: fixed; top: 20px; left: 0px; padding: 0px; margin: 0px; } .social { list-style: none; } .social a li { padding: 8px 12px; font-size: 25px; transition: all 0.8s ease-in-out; } .social a li:hover { margin-right: -30px; box-shadow: 2px 5px 10px grey; } .social a li:hover .fa { margin-left: 20px; } .fb_b { /* background-color: rgb(59, 89, 152);*/ background-color: rgba(65,103,178,255); } .twitter_r { /* background-color: rgb(29, 161, 242);*/ background-color: #000000; } .whatsapp_r { /* background-color: rgb(77, 194, 71);*/ background-color: rgba(13,191,67,255); } .fa-envelope_r { /* background-color: rgb(219, 68, 55);*/ background-color: #e2123d; } .fa-linkedin_r { background-color: rgb(0, 119, 181); } @media only screen and (max-device-width: 767px) { p span img { max-width: 90% !important; height: auto !important; } p img { max-width: 90% !important; height: auto !important; } h2 { font-size: 20px !important; font-weight: 600 !important; } h3 { font-size: 18px !important; font-weight: 600 !important; } } /* === Film Roll Badge Styling(IFFI2025 countdown) === */ .film-roll-badge { position: absolute; top:82%; right: 20px; width: 230px; height: 70px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 18px, #6e2b8b 18px, #6e2b8b 36px ); border-top: 8px solid #9a2375; border-bottom: 8px solid #9a2375; border-radius: 8px; overflow: hidden; box-shadow: 0 4px 12px rgba(0, 0, 0, 0.4); animation: moveFilm 8s linear infinite; z-index: 10; } /* film sprocket holes */ .film-roll-badge::before, .film-roll-badge::after { content: ""; position: absolute; width: 100%; height: 10px; background: repeating-linear-gradient( to right, #9a2375 0px, #9a2375 10px, #fff 10px, #fff 20px ); left: 0; z-index: 2; } .film-roll-badge::before { top: -4px; } .film-roll-badge::after { bottom: -4px; } .film-roll-inner { position: relative; height: 100%; display: flex; align-items: center; justify-content: center; animation: flicker 2s infinite ease-in-out; } .countdown-text { font-size: 1.3rem; font-weight: 700; color: #fff; text-shadow: 0 0 6px rgba(255, 255, 255, 0.4), 0 0 10px #000; white-space: nowrap; } /* === Animations === */ @keyframes moveFilm { 0% { background-position: 0 0; } 100% { background-position: 120px 0; } } @keyframes flicker { 0%, 100% { opacity: 1; } 50% { opacity: 0.9; } 25% { opacity: 0.95; } 75% { opacity: 0.85; } } /* === Responsive Adjustments === */ @media (max-width: 1500px) { .film-roll-badge { top: 68%; right: 18px; /* width: 220px; */ height: 65px; font-size: 0.85rem; } .press-section { margin-top: 35px; } } @media (max-width: 992px) { .film-roll-badge { top: 52%; right: 10px; width: 200px; height: 60px; } } @media (max-width: 768px) { .film-roll-badge { top: 56%; right: 10px; width: 124px; height: 55px; } .countdown-text { font-size: 0.9rem; } } @media (max-width: 576px) { .film-roll-badge { top: 59%; right: 5px; /* width: 160px; */ height: 50px; } .countdown-text { font-size: 0.85rem; } } const festivalStart = new Date("2025-11-20T00:00:00").getTime(); const festivalEnd = new Date("2025-11-28T23:59:59").getTime(); const countdownElement = document.getElementById("countdown"); const interval = setInterval(() => { const now = new Date().getTime(); // BEFORE FESTIVAL — show days + hours left if (now = festivalStart && now el.style.width = "350px"); clearInterval(interval); } }, 1000); //

Original PIB release
pib.gov.in · PRID 2236903

Open on PIB ↗

TDB-DST SUPPORTS BABYCUE PVT. LTD., CUTTACK (ODISHA) FOR DEVELOPMENT OF RAPID DIAGNOSTIC PLATFORM FOR CHILDHOOD DIARRHEA

More from this day